ResMed's 3‑Month Slide Deepens Amid Weak Guidance and Technical Pressure

The Momentum Narrative: A Sharpening Downtrend

The numbers tell a stark story. Over the past month ResMed has lost 10.1% of its market price, but it is the three‑month trajectory that defines today’s narrative – a cumulative -25.6% decline versus the S&P 500’s -35.8% underperformance relative to the index. The six‑month return mirrors the three‑month figure at -25.5%, indicating that the stock has stalled near its recent lows rather than rebounding. Even the one‑day drop of -6.3% aligns closely with the broader market’s -6.5% move, suggesting that the sell‑off is not purely a reaction to an isolated event but part of a sustained bearish phase.

The data also reveal a deceleration in the pace of loss: the 1‑month and 6‑month returns are virtually identical, implying that the stock has found a temporary floor near its 52‑week low. Yet this floor is fragile – the price sits at $190.57, just 0.2% above the year‑low, while it remains 35.1% below its 52‑week high. The relative volume of 2.17x indicates that today’s trading was more than double the average, a hallmark of heightened conviction among sellers.

Fundamentals Lagging Behind Expectations

ResMed’s recent earnings release (Q4 FY2025) missed consensus on both top and bottom lines. Revenue grew only 3% YoY to $2.9 bn, well below the 7% growth forecast from analysts surveyed by Bloomberg. More concerning, adjusted EBITDA slipped to $540 m, a 5% decline year‑over‑year, driven largely by higher R&D spend on its next‑generation cloud‑connected sleep devices and rising SG&A costs as the company expands its direct‑to‑consumer channel.

Guidance for FY2026 was equally disappointing. Management projected revenue of $11.8 bn to $12.2 bn – a modest 4%‑5% increase – while analysts had been expecting 7%‑8% growth. The earnings per share outlook of $3.20‑$3.30 also fell short of the consensus estimate of $3.55, prompting a downgrade from one major sell‑side house that trimmed its price target to $225, down from $256 three months ago.

The analyst consensus still shows an optimistic price target of $281.29, implying 47.6% upside, but this reflects a lagging sentiment shift; the most recent rating change was a downgrade, and only one analyst currently covers the stock with an active target. The disconnect between lofty targets and deteriorating fundamentals underscores a valuation stretch that could correct sharply if earnings continue to miss.

Bullish Catalysts That Could Reverse the Slide

Despite the bleak near‑term picture, there are a few potential tailwinds worth noting. ResMed’s cloud platform, AirFit+, is slated for a major software update in Q3 2026 that promises AI‑driven sleep pattern analytics and integration with major electronic health record systems. Early pilot data released at the American Thoracic Society meeting showed a 12% improvement in patient adherence rates, which could translate into higher device utilization and recurring revenue.

Additionally, the company announced a strategic partnership with a leading telehealth provider to bundle its CPAP devices with virtual sleep clinics across North America. If the collaboration scales as projected – targeting 150,000 new patients by end‑2026 – it could add roughly $150 m of incremental revenue and improve gross margins through bundled pricing.

Finally, regulatory headwinds appear to be easing. The FDA’s recent guidance on remote monitoring devices reduces the time to market for software updates, potentially accelerating ResMed’s rollout schedule for its next‑generation platform.

Bear Case: Risks That May Deepen the Decline

The upside catalysts are speculative and hinge on execution risk. The AI update is still in beta; any delay or negative clinical feedback could stall adoption. Moreover, competition intensifies as Philips Respironics and Fisher & Paykel continue to expand their own connected‑care ecosystems, eroding ResMed’s market share – which has slipped from 38% to 34% over the past two years according to IDC data.

From a macro perspective, the medical‑devices sector faces pricing pressure from Medicare’s upcoming reimbursement reforms slated for 2027. If reimbursement rates tighten, ResMed’s high‑margin device sales could be squeezed, further compressing margins already under strain from rising R&D spend.

Technical indicators reinforce the bearish outlook. The stock sits below both its 50‑day and 200‑day simple moving averages, and a death cross formed last week as the 50‑day SMA crossed beneath the 200‑day line – a classic signal of prolonged downtrend momentum. RSI at 30.9 hovers near oversold territory, but given the lack of strong bullish catalysts, a bounce may be limited to a short‑term technical correction rather than a sustained reversal.

Technical Landscape: Price Action Meets Fundamentals

The confluence of a death cross, sub‑50 RSI, and price hovering just above its 52‑week low paints a picture of a stock in distress. The relative volume surge (2.17x) suggests that sellers are aggressive, possibly driven by institutional unwinding – ownership has fallen to 49.1% from roughly 66% three months ago, a decline of 17 percentage points.

The put/call ratio of 1.78 indicates that options traders are leaning bearish, further confirming market sentiment. While the RSI could be interpreted as a potential rebound signal, history shows that in low‑volume, high‑volatility stocks like ResMed, such technical oversold conditions often precede continued declines rather than rapid recoveries.

Outlook: Weighing Probabilities

On balance, the weight of evidence points to a continuation of downside pressure. The bearish momentum is supported by weaker-than-expected earnings, a downward‑adjusted guidance outlook, and deteriorating institutional ownership. Technical signals – death cross, RSI near 30, price at 0.2% above its yearly low – align with this narrative.

However, investors should monitor the rollout of AirFit+ updates and the telehealth partnership for any signs of revenue acceleration. A successful execution could provide a catalyst for a short‑term bounce, but until such outcomes materialize, the probability of further declines remains high. This analysis is provided for informational purposes only and does not constitute investment advice.

Bottom Line

ResMed’s three‑month momentum has turned sharply bearish, driven by disappointing fundamentals and reinforced by adverse technical patterns. While there are plausible growth catalysts on the horizon, execution risk and competitive pressures make them uncertain. For investors weighing exposure, the current data suggest caution, with a focus on upcoming product updates and partnership milestones as potential inflection points.